Popular Articles
Natural Remedies

Nanobiotix Reports Exciting Preclinical Results Using Its NanoXray™ Therapeutics Technology To Destroy Tumors
Nanobiotix, an emerging nanomedicine company, announced exciting preclinical results using its patented nanoXray therapeutics platform to fight tumors. The preclinical study, performed at Institut Gustave Roussy, one of Europe"s leading cancer treatment centers, showed that an intratumoral injection of NBTXR3 nanoparticles and activated via standard radiation therapy led to complete tumor regression in mice at 60 days, compared to zero tumor regression in mice treated with xray only or NBTXR3 only. The study was led by principal investigator, Jean Bourhis, M.D., Ph.D. a prominent radiation oncologist and researcher at Institut Gustave Roussy.
generic viagra online
Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval To Proceed With Phase 3 Development Of OnaltaTM
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced that the European Medicines Agency (EMEA) has approved its Phase 3 protocol for Onalta (Yttrium-90 edotreotide). Onalta is the Company"s lead radiotherapeutic product candidate under development for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors in patients whose symptoms are not controlled by conventional therapy. The compound has shown the potential to selectively deliver lethal radiation to cancer cells. The proposed Phase 3 trial will confirm that administration of Onalta results in stabilization, regression or complete remission of the carcinoid tumor, and improves carcinoid-related symptoms when compared to a high-dose regimen of the current standard therapy for this disease, Sandostatin®. With EMEA"s approval of its proposed Phase 3 protocol in hand, Molecular Insight can proceed with the final clinical trial that will position Onalta for marketing authorization in the EU.
News of the day
NICE Issues Positive Final Appraisal Determination Recommending The Use Of Basilea's Toctino
Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that the National Institute for Health and Clinical Excellence (NICE) issued the Final Appraisal Determination (FAD) recommending the use of Toctino® (alitretinoin) within its licensed indication, as a treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids.
Medical Devices

New Study Shows Many Unplanned Quit Smoking Attempts Are Successful

Data published in the journal, Nicotine and Tobacco Research, shows that many U.S. quit attempts are unplanned and can be a successful route to cessation. In the study, almost 40 percent of subjects reported that their most recent quit attempt started without any advance planning, suggesting that for some smokers, setting an advance quit date may not be as necessary as once thought. While a period of planning prior to quitting has long been thought to allow smokers time to prepare themselves for their quit attempt, the study explores the various reasons as well as demographic and psychographic data which may contribute to a smoker deciding to quit spontaneously. "The study examines the possibility that while quit attempts may seem like spontaneous efforts on the surface, they may actually be the result of prolonged subconscious dissatisfaction with or concern about one"s smoking. The results do not discredit planning out a quit attempt, however, a smoker needs to determine what may be the best approach to ensure long-term cessation," said Dr. Saul Shiffman, professor in the departments of psychology and pharmaceutical science at the University of Pittsburgh and study co-author. "All smokers should consider ways to manage tough situations such as cravings and withdrawal symptoms to ensure long-term success." Smokers who make an unplanned quit attempt can improve their chances significantly by getting help and support from proven stop smoking tools such as therapeutic nicotine products like Nicorette(R), NicoDerm(R) CQ(R) and Commit(R). Consistent with their FDA-approved labeling, therapeutic nicotine products help reduce nicotine withdrawal symptoms, including nicotine craving, associated with quitting smoking. Smokers who quit spontaneously can also access therapeutic nicotine medicines which are available over the counter without a doctor"s prescription at more than 35,000 retail outlets. About the Study A study of 1,700 adults (900 adults age 18 and over who currently smoke cigarettes every day and 800 adults, age 18 and over, who previously smoked every day but quit between one month and ten years ago) were recruited from an online U.S. market research database (Survey Sampling International, Shelton, CT) and completed an online survey. Random samples of both panels were sent an e-mail that contained a link to an online survey. About GlaxoSmithKline Consumer Healthcare GlaxoSmithKline Consumer Healthcare is one of the world"s largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette(R) and NicoDerm(R)CQ(R), and Commit(R), as well as many medicine cabinet staples -- alli(R), Aquafresh(R), Sensodyne(R), and TUMS(R) -- which are trademarks owned by and/or licensed to GlaxoSmithKline Group of Companies. About GlaxoSmithKline GlaxoSmithKline - one of the world"s leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. GlaxoSmithKline Consumer Healthcare


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):